| n | Patients with ID treated in hepcidin arm (n = 53) | n | Patients with ID not treated in control arm (n = 102) | p |
---|---|---|---|---|---|
Primary outcome | Â | Â | Â | Â | Â |
Post-ICU LOS (days) | 53 | 42 (16; 90) | 102 | 29 (11; 90) | 0.37 |
Secondary outcomes | Â | Â | Â | Â | Â |
Number of days alive at home at day 90 | 53 | 50 (0; 76) | 102 | 61 (0; 82) | 0.21 |
Day 15 visit | Â | Â | Â | Â | Â |
Day 15 Hb (g/dL) | 40 | 10.7 ± 1.6 | 59 | 10.4 ± 1.4 | 0.24 |
Day 15 hepcidin (µg/L) | 19 | 35.7 (23.0; 53.7) | 31 | 18.0 (7.6; 44.0) | 0.04 |
Day 30 visit | Â | Â | Â | Â | Â |
Fatigue (scale 1–10) | 39 | 5.0 (3.0; 6.0) | 61 | 6.0 (3.0; 7.0) | 0.13 |
MFI-20 | Â | Â | Â | Â | Â |
 General fatigue (score 9–45) | 40 | 28 (22; 31) | 63 | 26 (18; 30) | 0.33 |
 Mental fatigue (score 6–30) | 40 | 25 (20; 28) | 63 | 25 (20; 28) | 0.75 |
 Reduced activity (score 3–15) | 40 | 8 (6;10) | 63 | 8 (6;11) | 0.66 |
 Reduced motivation (score 2–10) | 40 | 8.(6;10) | 63 | 8 (6; 10) | 0.24 |
Mortality | Â | Â | Â | Â | Â |
Death at day 90 | 53 | 2 (3.8) | 102 | 17 (16.7) | 0.02 |